NCT00052182View on ClinicalTrials.gov

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2002

Conditions
HIV Infections
Interventions
BIOLOGICAL

EP HIV-1090

Trial Locations (1)

80262

University of Colorado, Health Science Center, Denver

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00052182 - Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients | Biotech Hunter | Biotech Hunter